Atogepant
3 NDCs across 1 manufacturer|0 Generic,3 Brand
Atogepant is used to treat migraine disorders, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
The brand product was first FDA-approved on Sep 28, 2021. In 2024, Medicare Part D spent $260 million on Atogepant across 210,000 claims for 45,000 beneficiaries.
Atogepant is available as 3 NDCs from 1 manufacturer (0 generic, 3 brand), with NADAC prices from $38.39 to $38.45 per EA — a 0% difference between cheapest and most expensive. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
3
0G / 3B
Manufacturers
1
competing in market
Price Spread
$38.39 – $38.45
per EA
7d Activity
avg +0.0% WoW · of 3 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Manufacturer Breakdown
1 manufacturer producing ATOGEPANT
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
QULIPTA 60 MG TABLET | $38.4528 per EA | -0.03% |
QULIPTA 10 MG TABLET | $38.4287 per EA | +0.03% |
QULIPTA 30 MG TABLET | $38.3926 per EA | -0.01% |
Frequently Asked Questions
What is Atogepant used to treat?
Atogepant is used to treat migraine disorders, per the National Library of Medicine's MED-RT classification.
How much does Medicare spend on Atogepant?
In 2024, Medicare Part D spent $260 million on Atogepant across 210,000 claims for 45,000 beneficiaries.
How many Atogepant products are on the market?
The Atogepant drug market contains 3 NDCs from 1 manufacturer — 0 generic and 3 brand products.
What is the price range for Atogepant?
NADAC reference prices for Atogepant range from $38.3926 to $38.4528 per EA — a 0% difference between cheapest and most expensive.
Which manufacturers make Atogepant?
1 manufacturer lists Atogepant in NADAC. Ranked by number of NDCs, the largest are AbbVie Inc. (3).
How has the price of Atogepant changed recently?
Over the past 7 days, 1 Atogepant NDC rose and 2 fell, with a market-wide average change of +0.0%.